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The Janus kinase/signal transducer and activator of tran-
scription (JAK/STAT) signaling cascade plays an impor-
tant role in hematopoiesis. A constitutive activation of
this pathway is found in a broad variety of diverse human
and murine leukemias and lymphomas. Whereas STAT3
and STAT5 accelerate and initiate tumor formation, STAT1
is generally considered a tumor suppressor. As shown by
Kovacic et al. [1], STAT1 accelerates leukemia formation
by up-regulation of MHC class I on leukemic cells allow-
ing them to escape natural killer (NK) cell-mediated lysis.
In the present study we investigate the role of the STAT1
serine727 phosphorylation site for leukemia initiation
and progression. After retroviral leukemia induction
STAT1S727A knock-in mice show enhanced disease latency
compared to wild type (WT) mice. Upon injection of B16
melanoma cells, numbers of lung metastases were
increased in STAT1-/- recipients, but significantly reduced
in STAT1S727A mice when compared to WT mice. This indi-
cates that the effect of STAT1S727A may not be cell-intrinsic
but rather results from altered interactions with the host
immune system. Clearance of leukemic and B16 cells is
mainly mediated by NK cells. Therefore, differences in NK
cells might explain our in vivo data. As determined in a
[3H]thymidine incorporation assay, STAT1S727A NK cells
showed enhanced proliferation rates compared to WT
cells. Moreover, in a classical [51Cr]-release assay
STAT1S727A NK cells were able to lyse leukemic cells more
efficiently than WT NK cells. NK cells can be divided into
different functional subsets according to cell surface
expression of DX5, Mac-1 and CD27. Ex vivo fluorescence-
activated cell sorting (FACS)-based analysis revealed a dis-
tinct expression pattern in STAT1S727A NK cells (Mac-1+,
DX5+, CD27+), that is characteristic for a "pre-activated"
NK cell phenotype [2] and is found in STAT1S727A mice in
spite of the absence of any activating stimulus. These
experiments indicate that phosphorylation of STAT1
serine727 in NK cells is relevant for activation, cytolytic
function and as a consequence for their ability to eradicate
tumor cells in vivo.
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